Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Metabolic Inhibitor Development Services for Cancer

Using cutting-edge research methods and expertise in cancer biology, Alfa Cytology aims to identify and develop novel metabolic inhibitors that disrupt tumor growth and survival. We collaborate with research organizations and companies to accelerate the discovery and development of promising therapeutic candidates.

Introduction to Metabolic Inhibitor for Cancer

Metabolic inhibitors are a class of drugs that target specific metabolic pathways essential for the survival and proliferation of cancer cells. By selectively inhibiting specific enzymes or pathways involved in cellular metabolism, metabolic inhibitors effectively deprive cancer cells of the nutrients and energy they need for abnormal growth. Metabolic inhibitors are being developed to cover a variety of metabolic pathways critical to cancer cell survival, including glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism.

Fig. 1 Immunometabolism and microenvironment in cancer. Fig.1 Immuno-Metabolism and Microenvironment in Cancer. (Giannone, G., et al., 2020)

Examples of Metabolic Inhibitors

The following are common examples of metabolic inhibitors.

CB-839. A glutaminase inhibitor that disrupts glutamine metabolism in cancer cells.
Orlistat. An inhibitor of fatty acid synthase (FASN) that impairs lipid synthesis in cancer cells.
2-Deoxyglucose (2-DG). A glucose analogue that inhibits glycolysis by competitively inhibiting hexokinase.
Metformin. Originally used to treat diabetes, metformin has shown anti-cancer properties by inhibiting mitochondrial complex I and activating AMP-activated protein kinase (AMPK).

Our Services

Alfa Cytology's metabolic inhibitor development service is designed to meet the urgent need for innovative therapies targeting cancer metabolism. Our goal is to elucidate the complex metabolic pathways that drive cancer progression, and to identify, validate and optimize the efficacy of metabolic inhibitors while minimizing toxicity and improving therapeutic efficacy.

Services Provided for Metabolic Inhibitor Development

Our one-stop solution covers a wide range of services necessary for metabolic inhibitor development, including but not limited to the following.

Compound Screening and Optimization

Conducting high-throughput screening assays and medicinal chemistry optimization to identify lead compounds with optimal pharmacological properties.

In Vitro and In Vivo Pharmacology Studies

Performing preclinical studies to evaluate the efficacy and safety of metabolic inhibitors in cellular and animal models.

Target Identification and Validation

Utilizing advanced screening technologies and bioinformatics analysis to identify and validate novel metabolic targets.

Mechanism of Action Studies

Investigating the underlying mechanisms of metabolic inhibitors using biochemical, molecular, and imaging techniques.

Biomarker Discovery

Identifying predictive biomarkers through omics technologies to guide patient selection and therapeutic strategies.

Targets for Metabolic Inhibitor Development

We focus on the following key molecules and pathways involved in cancer, providing development services that include many different molecule types.

Development Types Targeting Glutamine and Arginine Metabolism

Development Types Targeting Adenosine Pathway

Small molecule inhibitors
Monoclonal antibodies
Adenosine receptor antagonists

Development Types Targeting Kynurenine Pathway

Alfa Cytology offers comprehensive solutions to address key challenges encountered in the field of cancer therapy development. With expertise and cutting-edge technology, we are committed to exploring new targets and strategies to disrupt cancer metabolism and halt tumor progression. For a consultation or to learn more about how we can support your innovative cancer therapy development program, please contact us.

Reference

Giannone, G., et al.; (2020). Immuno-metabolism and microenvironment in cancer: key players for immunotherapy. International journal of molecular sciences, 21(12), 4414.

For research use only.